Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06027905 · ClinicalTrials.gov registry record · NA

Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate

A NA study of Hypertension, sponsored by Rush University Medical Center.

Completed
Registry status
NA
Development phase
445
Enrollment target
1
Study location

NCT06027905 is a NA study of Hypertension that has completed, run by Rush University Medical Center. The registered enrollment target is 445 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06027905, a NA study of Hypertension, has completed, sponsored by Rush University Medical Center.

COMPLETED
Registry status
NA
Development phase
445 participants
Enrollment target
1
Study location

Study Summary

This study aims to decrease the racial gap in high blood pressure in African American and Latinx patients in Rush University Medical Center clinics.

Conditions Studied

Interventions

  • OTHER E3 Remote Monitoring and Social Intervention

Study Locations (1)

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 445 participants
Start Date 2023-09-13
Est. Completion 2025-05-12
Phase NA

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT06027905

The ClinicalTrials.gov registry entry for NCT06027905 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which E3 Remote Monitoring and Social Intervention is the first listed.

NCT06027905 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06027905 about?

NCT06027905 is a clinical study titled "Novartis - Closing the Gap in Cardiovascular Risk: Engage, Empower, Evaluate". This study aims to decrease the racial gap in high blood pressure in African American and Latinx patients in Rush University Medical Center clinics.

What is the current status of trial NCT06027905?

This trial is currently completed. It is a NA study. The enrollment target is 445 participants. The study started on 2023-09-13. Estimated completion is 2025-05-12.

What conditions does trial NCT06027905 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT06027905?

The interventions under investigation include: E3 Remote Monitoring and Social Intervention (OTHER).

Who is sponsoring clinical trial NCT06027905?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06027905 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.